Pharma BD Deal Intelligence
Alkermes paid $100M upfront for Rodin Therapeutics' preclinical HDAC-CoREST inhibitors worth up to $950M, but lead candidate ALKS 1140 was terminated in Phase 1 by 'Sponsor Decision' after just 20 patients, leaving the $850M milestone tail unrealized.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Alkermes' Rodin acquisition came on the heels of cost-cutting and was framed as a strategic pivot toward CNS depth; analysts noted Rodin's preclinical stage…
LifeSciVC framed the deal as a vindication of Atlas Venture's bold thesis that selective HDAC-CoREST inhibition could safely modulate epigenetic synaptogenesis…
Alkermes' bolt-on of Rodin was characterized as a pipeline-thickening move with milestone-heavy economics, though commentators questioned whether preclinical…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Alkermes acquired Rodin Therapeutics in November 2019 for $100M upfront plus up to $850M in clinical, regulatory and sales milestones (~$950M total; closed Nov 25, 2019). The deal added Rodin's preclinical, orally available, brain-penetrant CoREST-selective HDAC inhibitors targeting synaptopathies in neurodegenerative disease. The lead asset, ALKS 1140 (formerly RDN-929), entered a first-in-human Phase 1 study (NCT05019105) with first subject dosed in late 2021, but Alkermes terminated that study on Aug 23, 2022 by "Sponsor Decision" after enrolling 20 of a planned cohort. No successor HDAC-CoREST program has since appeared in Alkermes' pipeline: the company separated its oncology business (Mural Oncology) in November 2023 to become a pure-play neuroscience company centered on the orexin OX2R agonist ALKS 2680. The ~$850M milestone tail is therefore effectively unrealizable and the acquired program is discontinued.
Assessment window: 5yr post-close.
$1.5B US Alzheimer's drug market 2024 · ~7.2M Projected US AD patients aged 65+ in 2025
Alzheimer's disease and related synaptopathies are characterized by progressive synaptic loss and dysfunction in the brain, leading to memory impairment, cognitive decline, and ultimately loss of independence. Despite recent amyloid-targeted approvals, no therapy has restored or rebuilt synaptic connections — the structural deficit underlying symptoms — making epigenetic synaptogenesis approaches an attractive frontier.
The Alzheimer's market shifted decisively after the 2019 deal date with the FDA approvals of Biogen/Eisai's Aduhelm (2021, since withdrawn) and Leqembi (lecanemab, 2023), and Eli Lilly's Kisunla (donanemab, 2024), all anti-amyloid antibodies that modestly slow decline. Symptomatic options remain dominated by generic cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine, often combined as Namzaric. Rodin's selective HDAC-CoREST inhibitors offered a fundamentally different epigenetic synaptogenesis hypothesis — reactivating neuronal gene expression to strengthen and create new synapses, with a class profile designed to avoid the hematologic toxicity that plagued earlier pan-HDAC inhibitors (LifeSciVC: https://lifescivc.com/2019/11/thinking-boldly-alkermes-acquires-rodin-therapeutics/). Alkermes paid $100M upfront with $850M in milestones to expand from psychiatry into neurodegeneration. Outcome: Alkermes initiated a Phase 1 study of ALKS 1140 (the lead CoREST-selective HDAC inhibitor) in November 2021, but the asset has since been listed as discontinued and does not appear on Alkermes' 2024 pipeline disclosures, which now centers on orexin agonists (alixorexton/ALKS 2680) and commercial products Vivitrol, Aristada, and Lybalvi (FierceBiotech: https://www.fiercepharma.com/pharma/jpm24-after-transformational-year-alkermes-moves-pure-play-neuroscience-specialist).
Alkermes terminated the sole Phase 1 study (NCT05019105) of ALKS 1140 / RDN-929, the CoREST-selective HDAC inhibitor acquired from Rodin, on 2022-08-23 (Sponsor Decision). No successor HDAC-CoREST program has appeared in Alkermes' pipeline; the ~$850M milestone tail is effectively unrealizable.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Alkermes plc / Rodin Therapeutics, Inc. (this deal) | 2019 | $950M | — |
| Alkermes plc / Cephalon, Inc. (Vivitrol rights) | 2008 | $27M | 83 |
| Alkermes plc / Avadel Pharmaceuticals plc | 2025 | $2.1B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
← Browse all deals · How we score deals
More: 2019 deals · Alkermes plc deals · Neurology deals